Asabys Partners Integrates Aliath Bioventures Life Sciences Investment Platform in Strategic Move with AltamarCAM
- Strategic integration fuels Asabys’ goal to build a beyond €1 billion life sciences investment platform in Europe by 2030
- Asabys incorporates Aliath Bioventures’ experienced team with a successful track record
- Alta Life Sciences Spain I FCR fund to be co-managed by Asabys and AltamarCAM
MADRID and BARCELONA, Spain, Oct. 2, 2025 – Asabys Partners, a Spanish venture capital firm specialized in healthcare, and AltamarCAM Partners, a global investment firm specialized in private markets, have today agreed to integrate Aliath Bioventures (formerly Alta Life Sciences), AltamarCAM’s life sciences team, into Asabys and to jointly co-manage the Alta Life Sciences Spain I FCR fund. With the strategic unification, Asabys’ assets under management will expand from €300 million to over €400 million, significantly boosting its investment capacity, generating synergies, and ensuring continuity in creating value for investors.
